¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º j}h50*6KO  
(y(V,kXwa8  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ U/jJ@8  
CsuSg*#X+  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) RsrZ1dhPvV  
Xwx;m/  
1. ICAM-1 BAzqdG  
~ZvZ k  
2. interleukin 12(IL-12) nz>A\H  
%iJ6;V 4  
3. tumor infiltrating lymphocyte >8>.o[Q&  
!q7M+j4  
4. TCR/CD3 complex ;>Z#1~8  
)03.6 Pvs  
5. hematopoietin receptor family .cu5h   
CQv [Od  
6. individual idiotype(IdI) ]FFU,me2  
2<B+ID3qv  
7. integrin e3(0L I  
4)XN1r:  
8. colony-stimulatory factor (CSF) d(]LRIn~1  
!gT6S o  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© f_z2d+  
yK}#|b'cM  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? "KFCA9u-  
tX)]ZuEi$  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ +<3tv&"  
.Hgiru&  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ_$fxoD9  
: uI}"Bp  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ F htf4  
!N)oi $T%  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) TmQ2;3 %  
%!eK"DKG^  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ Y %<B,3  
'nCBLc8  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) bk>M4l61  
q.g!WLiI  
3. immunoglobulin superfamily (IgSF) f'#7i@Je  
rj:$'m7  
4. selectin Kh5:+n_X  
aV>w($tdd  
5. anti-idiotypic antibody (¦ÁId) !_c<j4O  
O^e !<bBd  
6. major histocompatibility complex(MHC) ?j $z[_K  
: ;d&m  
7. immunotolerance Q)Ppx7)  
O:u^jcXA  
8. biological reponse modifier(BRM) \x|(`;{  
S:t7U %  
9. immune reponse gene (Ir gene) i#Wl?(-i  
DVCc^5#  
10. reshaped antibody (or reconstituted antibody) 4q~l ?*S  
@9QHv  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© D6v 0n6w  
"b} ^ xy  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ hL8QA!  
Nzr zLK  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? d;'@4NX5+  
4RdpROK  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ 1{u;-pg  
wN*e6dOF  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? gp$+Qd  
*D|6g| Hb  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ P;A"`Il  
ch< zpo:  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? VS 8|lgQ  
i 5-V$Qh  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ }F@`A?k  
eo,m ^&  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ Mu{mj4Y{  
;ATk?O4T  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? dqG+hh^  
tCA |sN  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ XrBLw}lD`N  
<Oy%  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: LsBDfp5/  
}3N8EmS  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: 7p2x}[ .\  
{Y\hr+A  
ÃâÒßѧ Lmj?V1% V  
/>+JK5  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© T@k&YJ  
fzSZ>I0R  
1. CD8 Lw-j#}&6E  
'3 |OgV  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) `[Lap=.' .  
\Z57UNI  
3. immunoglobulin fold(Ig fold) y ?Q"-o (  
)(?s=<H  
4. cadherin (Ca-dependent cell adhesion moleculers) A6#ob  
Wx:_F;  
5. idiotype-anti-idiotypic antibody immune network theory ZwG+rTW  
iiRK3m  
6. HLA class II antigen y(N-1  
OE:t!66  
7. complementarity-determining region (CDR) vy-{BH  
hRA.u'M  
8. perforin(or pore-forming protein ,PFP) t7-sCC0  
5X~ko>  
9. high affinity IL-2 receptor sU{+.k{  
i*2z7MY  
10. artificial active immunization f1\x>W4z~\  
R HF;AX n  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 9Z#37)  
EB\z:n5  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠQ~*A`h#  
` 6"\.@4  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 uj8]\MY  
Fs&m'g  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ vTB*J,6.  
rj{'X  /  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ e HOm^.gd  
h` n>6I  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ A+[wH(  
kfmIhHlYQ  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? t_j.@|/FZ  
'TbA^U[  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ U&B~GJT+  
}1$8)zH  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ r2xlcSn%  
c%B=TAs5c  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ T;FzKfT|  
Wx XVL"  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ se)I2T{J  
cBm3|@7  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© JG4&eK$-  
Mz"kaO  
1. immunoglobulin gene rearrangement W C`1;(#G  
j5 ui  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) Lnj5EY er  
5hDE&hp  
3. flow cytometry(FCM) >#8`Zy:/Y  
gjs-j{*  
4. carrier effect V];RQWs  
T]i~GkD\  
5. positive selection of T lymphocytes in thymus f<zh-Gq  
X0=R @_KY  
6. mouse TH1(Th1) and TH2(Th2) subsets :x;D- kZ  
1yE~#KpH  
7. perforin (pore-forming protein ,PFP) _c #P  
m<076O4|`  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) [S9n F  
Y< M }'t  
9. SH-2(src-homology region 2) eM~i (]PY  
P0 89Mh9  
10. Ab2¦Â (internal image) ^.<IT"  
}- +;{u  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ;j52a8uE'}  
i?|SC=  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? I]$kVa1iN  
"iKK &%W  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? 3yZ@i<rfH  
MQ,2v. vZ.  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ\[8I5w-  
pFG~XW  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ @%jzVF7  
"%Rx;xw|  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠjwE<}y I  
,qr)}s-  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) ] #J ]f  
*X)OdU  
ÃâÒßѧרҵ£º _]Hn:O"o  
h<QXr'4+  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ g:*yjj  
T&{EqsI=B  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? lc'Jn$O@  
'Y-c*q  
´«È¾²¡Ñ§×¨Òµ£º N,;Bl&EU  
lw Kr$X4  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ mM95BUB  
PVvG  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ !u=[/>  
OgzPX^q/=  
Ïû»¯×¨Òµ£º d:j$!@o  
sNNt0q(  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ kdF# Nm  
i,V~5dE[I<  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? 19lx;^b  
}t-{,0  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ l~\'Z2op   
2R)Y}*VX  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© /FQumqbnt  
2B*9]AHny  
1. Fas(CD95)/FasL dvUJk<;w  
udw5A*Ls  
2. common chain of cytokine receptor Qn6&M  
{o;J'yjre1  
3 . TCR/CD3 complex ~s !+9\Fi  
J%%nv5y  
4. negaive selection of thymocytes F+}MW/ra@  
;Cv x48  
5. artificial active immune #LcF;1o%o2  
I*'QD)  
6. anti-idiotypic ?z? IEj}  
qex.}[  
7. IgSF >7 4'g }  
x! Z|^q  
8. Integrin "tm2YUG},s  
K /. ;N.9  
9. chemokine M$|^?U>cm  
X}_kLfP/9  
10. B7/CD28 z$S)|6Q  
bluhiiATd  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© !,|yrB&`S  
)ASI 4 1  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ D/Bb)]9I  
5%uLs}{\q  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ L%I@HB9-Q0  
S9U`-\L0  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ x2(hp  
FG'F]f c%  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ QGn3xM66  
K+2<{qwh  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ o[&*vc)  
Xw_AZ-|1D  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ ~*ST fyFw  
[y&yy|*\  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© {f<2VeJ  
=0 mf   
1. B7/CD28 NirG99kyo  
9jBP|I{xI  
2. Th1 subset |eU{cK~e^  
Lzm9Kh;  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© M&wf4)*%0+  
o/t^rY y  
4. antibody affinity maturation 4"at~K` Q  
`O/1aW1  
5. AP-1 PFq1Zai}n|  
:2ILN. &  
6. single chain variable fragment£¨ScFv£© ] -iMo 4H  
Z8I  Y!d  
7. NK cell receptor `n)e] dn  
}V jg>"  
8. Zinkernagel-Doherty phenomenon 3)cH\gsg9  
w#0/&\ b=  
9. Ig fold !Pd@0n4  
$S(<7[Z  
10. CD40/CD40L PuO5@SP~  
\USl 9*E  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© vJI]ZnL{  
 %JoHc?  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ ZP-^10  
5y^I~"_ i  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ y Ny,$1  
BLaF++Fop  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ W=G8l%  
FT8<a }o  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ 'Hf+Y/`  
G'#Uzwo  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ U\y:\+e l  
>dK# tsp  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ &s^t~>Gpr  
_|jEuif  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ xyzYY}PS  
zQ~N(Jj?h  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© &TT vX% T  
4 ++ &P9  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© xYp-Y"a.  
l~ Hu#+O  
1.Co-stimulators (or co-stimulating molecules) 3D}Pa  
q:cCk#ra  
2.NK-kB `c)[aP{vN  
Xk] uXx:TN  
3.Immunoglobulin superfamily U6?3 z  
Ak kth*p  
4.antigen-presenting cell (APC) }IRD!  
Z~AgZM R  
5.death domain #EA` |  
cv5+[;(b  
6.CCR and CXCR PO nF_FC  
LGh#  
7.Lectin (or mitogen) cO8yu`4!e  
7H g;SK6t0  
8.Clusters of differentiation, CD) ':|E$@$W  
\E1CQP-  
9.B7 family kq*IC&y  
 eIj2(q9  
10.Cytotoxic T lymphocyte, CTL) Mtaky=l8~I  
BsR3$  
11.IL-15 and IL-15 receptor (IL-15R) ^|%N _ s  
pS "A{k)i  
12.MHC restriction 4N)45@jk[  
&,QBJx<#  
13.Affinity-chromatography =, 64Qbau  
<u  ImZC  
14.Cyctosprin A, CsA &8dj*!4H  
]P2Wa   
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) N97WI+`  
l'1_Fb  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© &x3R+(H {  
zUA -  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 U9XOs)^  
CN6b 982&  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ ?]\v%[ho  
gWl49'S>+  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ ^V"08  
0KN'\KE  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© v807)JwS  
;It 1i` !R  
ÃâÒßѧרҵ£º p[%B#(]9,  
#;\tgUQ  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ + 7nA; C  
~"cqFdnO  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ lGEfI&1%!  
~V/?/J$  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ 8ZNwo  
t x1(6V&l;  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) H,)2Ou-Wn  
(X|lK.W y  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) `o%Ua0x2  
%`j2?rn  
1. ADCC(antibody dependent cell-mediated cytotoxicity) b|U3\Fmc  
cC$E"m  
2. »·æß¾úËØ(cyclosporin)  KRh?{  
= $6 pL  
3. KIR(killer cell inhibitory receptor) _'P!>C!  
*%QTv3{  
4. HLDA(human leucocyte differentiation antigen) 5dhT?/qvc  
HNV"'p;  
5. Interleukin 18(IL-18) Q46sPMH+_  
Nk shJ2  
6. ÕûºÏËØ(integrin) R1\$}ep^  
fYgX|#Me  
7. Fas/FasL v,mn=Q&9  
D4ud|$s1  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) 1 =9 Kwd  
}'Yk #Q  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) 1ogh8%  
M2y"M,k4  
10. Th1/Th2 n*i1QC  
@W*Zrc1NF  
11. »ùÒòÒßÃç(DNAÒßÃç) GA@Zfcg  
I)F3sS45}  
12. chemokines and chemokine receptor Ov9kD0S  
>-YWq  
13. ÃâÒßÄÍÊÜ yX;v   
zmh3 Q a(  
14. ¹²´Ì¼¤·Ö×Ó }u8D5Q<(  
^DS+O>  
15. ËÀÍö½á¹¹Óò(death domain) pZe:U;bb  
~F9WR5}]  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) QH_I<Y:n  
p;m2RHYF  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? vd'd@T  
- g]g  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦ÓᣠMPmsW &  
2u|} gZts  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î Qs.g%  
0 SeDBs  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ |KxFi H  
?4i:$.A Y  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå 'Nbae-pf  
s`:-6{E  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ (C EXPf  
;/8oP ;X2  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) }{Ncww!iN  
)m Uc !TP  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ 2So7fZa^wg  
dM1)wkbET  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿  `9  
~"+Fp&[9f  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»